Bruce Power has received approval from the Canadian Nuclear Safety Commission (CNSC) to operate its on-site hot cell facility, marking a significant milestone in the company’s continued leadership in the production of cancer-fighting medical isotopes. The CNSC’s approval authorizes Bruce Power to use the facility to perform Target Carrier Removal (TCR), an important step in the production process for lutetium-177 (Lu-177), a medical isotope used…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.